In conclusion, in older patients with AML, ASCT can be safely offered to the subgroup with CBF and NPM1 mutations in the absence of an FLT3 mutation, provided that an adequate number of PBSCs are collected. This evidence concerns the gene FLT3 and acute myeloid leukemia.